833 – Efficacy and Safety of Ustekinumab As Maintenance Therapy in Ulcerative Colitis: Week 44 Results from Unifi
Bruce E. Sands(Icahn School of Medicine at Mount Sinai), Colleen Marano(Johnson & Johnson (United States)), María T. Abreu(Icahn School of Medicine at Mount Sinai), William J. Sandborn(University of San Diego), Tadakazu Hisamatsu(Kyorin University), Laurent Peyrin‐Biroulet(Délégation Centre-Est), Silvio Danese(IRCCS Ospedale San Raffaele), Stephan R. Targan(Cedars-Sinai Medical Center), Hongyan Zhang(Tianjin University), Christopher D. O’Brien(Cedars-Sinai Medical Center), Philippe Szapary(Cedars-Sinai Medical Center), Gert A. Van Assche, Jewel Johanns(Johnson & Johnson (United States)), Remo Panaccione(University of Calgary)
Cited by 1
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
A Genome-Wide Association Study Identifies <i>IL23R</i> as an Inflammatory Bowel Disease Gene
|Science|2006|3k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k